lol646b

lol646b TikToker arrested after filming herself getting ready to steal from Target, police sayInvestec Champions Cup Pool 2: Bath 20 La Rochelle 24 Ronan O’Gara’s La Rochelle had just enough in the tank for a priceless away win in their Investec Champions Cup opener against Bath on Friday night. Twice-winners La Rochelle triumphed 24-20 at the Recreation Ground, after the Gallagher Premiership leaders launched a powerful second-half fightback, scoring two converted tries from 15 points adrift. La Rochelle roared clear through tries from flanker Oscar Jegou, prop Reda Wardi and scrum-half Tawera Kerr-Barlow, while fly-half Ihaia West kicked three conversions and a penalty. Bath were in deep trouble at half-time, managing only two Finn Russell penalties, yet they stirred after the break as hooker Tom Dunn and former Connacht and Ireland lock Quinn Roux claimed touchdowns, with Russell adding the extras. Despite swirling rain and a gusting wind, a compelling contest unfolded, although it ramps up pressure on Bath, despite claiming a losing bonus-point, to potentially win at least two of their last three pool games as they chase a last-16 place. They tackle Benetton in Italy next, with Clermont Auvergne and Leinster looming as testing opponents in January. Russell kicked Bath into a fifth-minute lead, but conditions — albeit at the very early stages of Storm Darragh — played their part. La Rochelle’s heavyweight pack soon warmed to the task, and relentless pressure close to Bath’s line resulted in an 18th-minute try for Jegou that West converted. The visitors had a collective power up-front, and they showcased it in all its glory through a long-range lineout drive that Bath could not stop. Wardi claimed the touchdown, with West adding the extras, and although Russell kicked a second penalty, La Rochelle were immediately back on the attack. Another lineout gave them a strong foundation five metres out, but this time they did not have to keep it tight as Kerr-Barlow darted through a huge gap for try number three, with West’s conversion making it 21-6. Bath reduced their deficit midway through the third quarter as Dunn touched down following a driven lineout, before Russell judged his touchline conversion brilliantly to leave his team eight points adrift. Bath struck again five minutes later after Kerr-Barlow failed to ground a kick behind own line, with a charging Roux capitalising and Russell converting. West eased La Rochelle nerves through a penalty on the hour-mark. Bath: Tries: Dunn, Roux. Cons: Russell 2. Pens: Russell 2. La Rochelle: Tries: Jegou, Wardi, Kerr Barlow. Cons: West 3. Pens: West. BATH: de Glanville, Cokanasiga, Redpath, Butt, Muir, Russell, Schreuder, du Toit, Dunn, Stuart, Roux, Ewels, Hill, Pepper, Reid. Subs: Ojomoh for Butt (73), Van Wyk for du Toit (65), Annett for Dunn (55), A. Griffin for Stuart (65), Molony for Roux (65), Bayliss for Hill (65), Coetzee for Reid (55). LA ROCHELLE: Dulin, Nowell, Seuteni, Danty, Leyds, West, Kerr Barlow, Wardi, Latu, Atonio, Lavault, Skelton, Jegou, Haddad, Alldritt. Subs: Reus for West (73), Penverne for Wardi (71), Lespiaucq-Brettes for Latu (61), Colombe for Atonio (61), Botia for Haddad (65). Referee: Andrew Brace (IRFU).Why Is ChatGPT's Santa Mode Only For Ages 13 And Up?

Ireland’s premier has spoken to the Dublin woman who won a civil case against mixed martial arts fighter Conor McGregor to praise her courage. Taoiseach Simon Harris said he also wanted to tell Nikita Hand, a hair colourist from Drimnagh, that her case had prompted an increase in women coming forward to ask for support. Ms Hand, who accused the sportsman of raping her in a Dublin hotel in December 2018, won her claim against him for damages in a civil case at the High Court in the Irish capital on Friday. The total amount of damages awarded to Ms Hand by the jury was 248,603.60 euro (£206,714.31). Mr McGregor said in a post on social media on Friday that he intends to appeal against the decision. That post has since been deleted. Speaking to the media on Saturday, Mr Harris said he told Ms Hand of the support she has from people across Ireland. “I spoke with Nikita today and I wanted to thank her for her incredible bravery and her courage,” he said. “I wanted to make sure that she knew how much solidarity and support there was across this country for her bravery. “I also wanted to make sure she knew of what the Dublin Rape Crisis Centre had said yesterday – that so many other women have now come forward in relation to their own experiences of sexual abuse as a result of Nikita’s bravery.” The Dublin Rape Crisis Centre said the case has had a “profound effect” on the people the charity supports, and that over the first 10 days of the High Court case, calls to its national helpline increased by almost 20%. It said that first-time callers increased by 50% compared to the same period last year, and were largely from people who had experienced sexual violence who were distressed and anxious from the details of case and the views people had to it. Mr Harris said: “I wanted to speak with her and I wanted to wish her and her daughter, Freya, all the very best night, and I was very grateful to talk with Nikita today. “Her bravery, her courage, her voice has made a real difference in a country in which we must continue to work to get to zero tolerance when it comes to domestic, sexual and gender-based violence. “I don’t want to say too much more, because conscious there could be further legal processes, but I absolutely want to commend Nikita for her bravery, for her courage, for using her voice.” Justice Minister Helen McEntee praised Ms Hand’s bravery and said she had shown “there is light at the end of the tunnel”. She said: “I just want to commend Nikita for her bravery, for her determination and the leadership that she has shown in what has been – I’ve no doubt – a very, very difficult time for her and indeed, for her family. She added: “Because of wonderful people like Nikita, I hope that it shows that there is light at the end of the tunnel, that there are supports available to people, and that there is justice at the end of the day.” Ms Hand said in a statement outside court on Friday that she hoped her case would remind victims of assault to keep “pushing forward for justice”. Describing the past six years as “a nightmare”, she said: “I want to show (my daughter) Freya and every other girl and boy that you can stand up for yourself if something happens to you, no matter who the person is, and justice will be served.” During the case, Ms Hand said she was “disappointed and upset” when the Director of Public Prosecutions (DPP) decided not to prosecute the case after she made a complaint to the Irish police. In a letter to her in August 2020, the DPP said there was “insufficient evidence” and there was not a reasonable prospect of conviction. Ms Hand asked the DPP to review the decision, saying she felt she was being treated differently because one of the suspects was famous. Asked about the DPP’s decision not to prosecute, Mr Harris and Ms McEntee stressed the importance of the DPP’s independence on whether to prosecute. “There are obviously structures in place where the DPP can meet a victim and can outline to them their reasons for not taking the case,” Mr Harris said. “But there’s also always an opportunity for the DPP in any situation – and I speak broadly in relation to this – to review a decision, to consider any new information that may come to light, and I don’t want to say anything that may ever cut across the ongoing work of the DPP.” Ms McEntee stressed that there should “never be any political interference” in the independence of the DPP’s decisions. “I have, since becoming minister, given priority to and enabled a new office within the DPP to open specifically focused on sexual offences, so that this issue can be given the focus and the priority that it needs,” she said. We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate.Procter & Gamble “stays the course”, say Deutsche Bank, Jefferies analysts

Sky News host Peta Credlin has launched a scathing attack on Victorian Opposition Leader John Pesutto following his defamation loss to independent MP Moira Deeming. Justice David O'Callaghan on Thursday found Mr Pesutto defamed Ms Deeming by painting her as a Nazi symathiser in comments following a 2023 women’s rally Ms Deeming attended which was gatecrashed by neo-Nazis. The judge awarded Ms Deeming $300,000 in damages as he delivered his decision in Melbourne's Federal Court. Mr Pesutto refused to resign from the Liberal Party in the aftermath of the case, vowing to “continue in this role, now more than ever”. Credlin has hailed the “massive win” for Ms Deeming, who had been expelled from the Victorian Liberal partyroom in the aftermath of the rally, but said she believes Mr Pesutto's position to be "untenable". Credlin argued the claims against Ms Deeming should “never have been made” and condemned Mr Pesutto for showing himself to be a "weak little man”. “The job of a party leader is not to be easily intimidated by an opponent that peddles lies; it's your job as leader to stand up to those lies, stand up for your team, particularly when your own side is unfairly under attack,” she said. Credlin said Victoria “desperately needs change” of leadership but this would require the Liberal Party to “offer a viable alternative”. She argued Mr Pesutto may have been capable of redemption if he was willing to accept his wrongdoing to Ms Deeming, reinstate her and apologise but said this was unlikely to happen. "It can't happen to a man that's been hit with a slam dunk as he has been by the judge and still thinks he's the bloody messiah,” she said. “If the Liberal Party in Victoria wants to be worthy of the very name, it has to find a new and better leader, if it wants to turn this around, it has to find a new and better leader, If it wants to restore faith, it has to find a new and better leader. “Today, Pesutto denied his position was untenable – but as things stand, it's the Liberal Party's position that's now untenable, with a Leader who makes things up, who damages people; and who won't apologise or make amends, even when he's found out in a court of law." Credlin said if she were on the Liberal frontbench, she would resign because, “my integrity would be worth more than any title that man could offer me”. “In all good conscience I could never serve under any leader who uses the slur of Nazism to try and destroy another Liberal and then is found by courts to have defamed someone using those words." In paragraph 696 of the judgment, Justice David O'Callaghan said Mr Pesutto’s “urgency” to publish claims against Ms Deeming was “driven more by a fear of the political damage that would be inflicted” on his leadership by then premier Daniel Andrews than by his “professed concern that the party and the parliament would be brought into disrepute”. “So, reckons the judge, the Victorian Liberal leader made untrue and highly damaging claims against a colleague in order to save himself from political attack,” Credlin said. “That, and these are my words, he was so spooked by Daniel Andrews – as every Liberal in this bloody state – that he threw Deeming under the bus in order to save his own skin – and in the process, has done vast damage to an innocent woman's reputation.”

Ousted former Syrian dictator Bashar al-Assad has found asylum in Russia after fleeing his country on Sunday, according to Kremlin sources quoted in the international media. Russian President Vladimir Putin had propped up the Assad regime for ten years, an extension of Soviet-era support. But with troops tied down in Ukraine, he could not help defend the regime when Syrian rebels began advancing after Hezbollah had been decimated by Israel in the Lebanon war. The BBC reported : “Deposed Syrian President Bashar al-Assad and his family have arrived in Moscow, Russian state media agencies report, citing sources in the Kremlin.” It added that Russian sources reported that Assad had been given asylum, noting that the BBC had not been able to verify those reports. Russia had supported Syria since a botched diplomatic effort by President Barack Obama to rid Syria of its chemical weapons led to Putin restoring a Kremlin foothold in the Middle East. Currently, there are still Russian naval forces in the Syrian coastal city of Latakia on the Mediterranean. Despite Russian and Iranian support for the regime, the Syrian rebels appeared to advance over the past two weeks almost without resistance, until reaching Damascus early Sunday morning. There were reports that Assad’s escape flight may have crashed, but those now appear to describe a separate flight. Joel B. Pollak is Senior Editor-at-Large at Breitbart News and the host of Breitbart News Sunday on Sirius XM Patriot on Sunday evenings from 7 p.m. to 10 p.m. ET (4 p.m. to 7 p.m. PT). He is the author of The Agenda: What Trump Should Do in His First 100 Days , available for pre-order on Amazon. He is also the author of The Trumpian Virtues: The Lessons and Legacy of Donald Trump’s Presidency , now available on Audible. He is a winner of the 2018 Robert Novak Journalism Alumni Fellowship. Follow him on Twitter at @joelpollak . Photo: file

Aaron Judge receives votes to be New York Supreme Court judge

Thanksgiving Weekend Sports Guide: Your roadmap to NFL matchups, other games, times, oddsNone

Oak Valley Bancorp Stock Hits All-Time High at $30.81Travis Kelce's Ex Kayla Nicole Makes Rare Comment On Their Breakup

49ers QB Brock Purdy, DE Nick Bosa out, Brandon Allen to start at Green BayMedia Release COPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE ® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment with epcoritamab The data were selected as part of the 2024 American Society of Hematology’s (ASH’s) Annual Meeting Press Program in the Diagnosing and Treating Blood Cancers and “Almost Cancers” briefing Genmab A/S (Nasdaq: GMAB ) today announced results from the Phase 1b/2 EPCORE ® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in difficult-to-treat adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab monotherapy. These results, from the monotherapy expansion (EXP) cohort (n=23) of the trial, along with the first safety data from the optimization (OPT) cohort, were presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), during the ASH Annual Meeting Press Program. The data will be presented during an oral session on December 9, 2024. In the EXP cohort, the median time to response was two (2.0) months and the median time to CR was 5.6 months. Among all patients in the cohort, median progression-free survival (PFS) was 12.8 months and median overall survival (OS) was not reached (median follow-up was 22.8 months). An estimated 65 percent of patients were alive at 15 months. Among 12 responders evaluable for minimal residual disease (MRD) by next-generation sequencing in peripheral blood, nine patients (75 percent) had undetectable MRD. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) in the EXP cohort were cytokine release syndrome (CRS; 96 percent), diarrhea (48 percent), peripheral edema (48 percent), fatigue (43 percent), and injection-site reaction (43 percent). Cytopenias were common (anemia, 65 percent; thrombocytopenia, 65 percent; neutropenia, 48 percent); however, most patients had baseline anemia and thrombocytopenia, suggesting that these events were largely disease-related. Three cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported (one Grade 1; two Grade 2), and there was one clinical tumor lysis syndrome (CTLS) case (Grade 2). These cases did not lead to treatment discontinuation. Four fatal TEAEs occurred - two cases of pneumonia, one case of sepsis and one case of squamous cell carcinoma of the skin. The EXP cohort followed a 2-step step-up dose regimen, and CRS was manageable and primarily low grade (9 percent Grade 1, 70 percent Grade 2, 17 percent Grade 3). In the first data from the separate OPT cohort, which followed a 3-step step-up dose regimen, CRS severity was substantially reduced with only low-grade events (71 percent Grade 1, 12 percent Grade 2). In both cohorts, CRS events primarily occurred following the first full dose, and none led to treatment discontinuation. No ICANS or CTLS cases were reported in the OPT cohort. “These EPCORE CLL-1 data are encouraging, especially as the majority of patients were heavily pre-treated with at least four lines of therapy,” said Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus, Professor and Director of Early Clinical Therapeutics and Associate Director of the Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. “Despite progress in treating chronic lymphocytic leukemia, there remains a tremendous need for additional therapeutic options for high-risk patients whose disease has progressed following standard chemoimmunotherapy and targeted therapies.” Additional data from the EXP cohort showed high response rates in patients with high-risk factors treated with epcoritamab, including TP53 aberrations, IGHV-unmutated disease and double-exposed disease – prognostic markers that are associated with disease progression and decreased survival. i , ii , iii In patients with TP53 aberrations (n=15), the ORR was 67 percent with a CR of 33 percent. Among patients with IGHV-unmutated disease (n=16), the ORR was 63 percent, and the CR was 44 percent. In double-refractory patients, the ORR was 53 percent, and the CR was 37 percent. All patients in the trial had prior chemoimmunotherapy, and most patients had previously received targeted therapies such as BTK and BCL2 inhibitors (double-exposed) and had high-risk disease characteristics. “Chronic lymphocytic leukemia is incurable, and patients often need a variety of treatments throughout their lifetime, especially if their disease has high-risk prognostic factors, has relapsed or has become refractory to the current standard-of-care, including targeted therapies,” said Dr. Judith Klimovsky, Executive Vice President & Chief Development Officer, Genmab. “These early data show the potential therapeutic applicability of epcoritamab in relapsed or refractory chronic lymphocytic leukemia, and further reinforce the potential of epcoritamab as a core therapy for the treatment of B-cell malignancies.” Use of epcoritamab in CLL is not approved in the U.S. or in the EU or in any other territory. The safety and efficacy of epcoritamab for use in CLL have not been established. About Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affecting over 200,000 people in the United States alone. iv Chronic lymphocytic leukemia can be classified as either slow growing (indolent) or fast growing (aggressive). v CLL is incurable, and many patients will likely relapse and progress on frontline therapies. vi Most patients will experience consecutive episodes of disease progression and will require several lines of treatment in their lifetime. vii , viii About the EPCORE ® CLL-1 Trial EPCORE ® CLL-1 is a Phase 1b/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of epcoritamab as a monotherapy and in combination with standard of care agents in patients with difficult-to-treat relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), R/R small lymphocytic lymphoma (SLL) and Richter's Syndrome (RS). The trial consists of two parts: a dose-escalation phase (Phase 1b) and an expansion phase (Phase 2). Patients with RS are only included in the expansion phase. The primary objective of Phase 1b is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of epcoritamab monotherapy and epcoritamab plus venetoclax in participants with R/R CLL. The purpose of Phase 2 is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab plus venetoclax for patients with R/R CLL and SLL. Additionally, epcoritamab monotherapy and combination therapy will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 04623541). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. ix Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigator’s choice chemotherapy ( NCT04628494 ), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL ( NCT05578976 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with R/R FL ( NCT05409066 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) compared to chemoimmunotherapy in patients with previously untreated FL ( NCT06191744 ), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL ( NCT06508658 ). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . Contact: David Freundel, Senior Director, Global R&D & Portfolio Communications T: +1 609 430 2481; E: dafr@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; HexaBody ® ; DuoHexaBody ® , HexElect ® and KYSOTM. EPCORE ® , EPKINLY ® , TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Campo, et al. TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics. Haematologica . 2018 Nov 15;103(12):1956–1968. https://haematologica.org/article/view/8691 .. ii Galieni, et al. Unmutated IGHV at Diagnosis in Patients With Early Stage CLL Independently Predicts for Shorter Follow-Up Time to First Treatment (TTFT). Leukemia Research. 2024. https://doi.org/10.1016/j.leukres.2024.107541 . iii Zuber, et al. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review. Cancer Medicine . 2024. https://doi.org/10.1002/cam4.70258 iv Fedele, et al. Chronic Lymphocytic Leukemia: Time to Care for the Survivors. Journal of Clinical Oncology . 2024. https://ascopubs.org/doi/10.1200/JCO.23.02738 . v Penn Medicine. Chronic Lymphocytic Leukemia (CLL). Accessed November 2024. https://www.pennmedicine.org/cancer/types-of-cancer/leukemia/types-of-leukemia/chronic-lymphocytic-leukemia . vi Odetola, et al. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Curr Hematol Malig Rep . 2023 Jun 6:1–14. doi: 10.1007/s11899-023-00700-z vii Moreno, Carol. Standard Treatment Approaches for Relapsed/Refractory Chronic Lymphocytic Leukemia After Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program . 2020 Dec 4;2020(1):33-40. doi: 10.1182/hematology.2020000086. viii Leukemia & Lymphoma Society. Relapsed and Refractory CLL. Accessed November 2024. https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/relapsed-and-refractory . ix Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine . 2020;52:102625. doi: 10.1016/j.ebiom.2019.102625. Media Release no. i19 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment 081224_MRi19_Epcor CLL ASH Data GLOBAL

Utah Jazz @ Portland Trail Blazers Current Records: Utah 4-17, Portland 8-14 When: Friday, December 6, 2024 at 10 p.m. ET Where: Moda Center at the Rose Quarter -- Portland, Oregon TV: KATU 2.2 ABC Follow: CBS Sports App Online streaming: fuboTV (Try for free. Regional restrictions may apply.) Ticket Cost: $9.49 The Portland Trail Blazers will face off against the Utah Jazz at 10:00 p.m. ET on Friday at Moda Center at the Rose Quarter. Both of these teams will be looking for a pick-me-up after considerable defeats in their previous games. The Trail Blazers are hoping to turn things around on Friday after a slow start to the season, which is looking a lot like last year's. They fell victim to a bruising 127-105 defeat at the hands of the Clippers on Tuesday. Portland has now taken an 'L' in back-to-back games. Meanwhile, the Jazz's recent rough patch got a bit rougher on Tuesday after their fifth straight loss. Their painful 133-106 defeat to the Thunder might stick with them for a while. For those keeping track at home, that's the biggest loss Utah has suffered against Oklahoma City since March 3, 2023. Portland's defeat dropped their record down to 8-14. As for Utah, their loss dropped their record down to 4-17. Looking forward, the Trail Blazers are expected to win a tight contest, barring any buzzer beaters. This will be their first time playing as the favorites at home this season. The Trail Blazers came up short against the Jazz when the teams last played back in December of 2023, falling 122-114. Can the Trail Blazers avenge their defeat or is history doomed to repeat itself? We'll find out soon enough. Portland is a slight 2.5-point favorite against Utah, according to the latest NBA odds . The oddsmakers had a good feel for the line for this one, as the game opened with the Trail Blazers as a 3.5-point favorite. The over/under is 226 points. See NBA picks for every single game, including this one, from SportsLine's advanced computer model. Get picks now . Utah has won 6 out of their last 10 games against Portland. Dec 14, 2023 - Utah 122 vs. Portland 114 Dec 02, 2023 - Utah 118 vs. Portland 113 Nov 22, 2023 - Portland 121 vs. Utah 105 Nov 14, 2023 - Utah 115 vs. Portland 99 Mar 22, 2023 - Portland 127 vs. Utah 115 Jan 25, 2023 - Portland 134 vs. Utah 124 Dec 03, 2022 - Portland 116 vs. Utah 111 Nov 19, 2022 - Utah 118 vs. Portland 113 Apr 10, 2022 - Utah 111 vs. Portland 80 Mar 09, 2022 - Utah 123 vs. Portland 85